Literature DB >> 9755905

The roles of depot injection sites and proximal lymph nodes in the presystemic absorption of fluphenazine decanoate and fluphenazine: ex vivo experiments in rats.

J P Luo1, J W Hubbard, K K Midha.   

Abstract

PURPOSE: The release and presystemic absorption of fluphenazine and its decanoate ester from intramuscular depots were investigated.
METHODS: Rats were sacrificed in groups of three at various times after injection of drug or prodrug in sesame oil. Muscle tissues at the injection sites and various lymph nodes were excised. Blood (plasma) was harvested by cardiac puncture.
RESULTS: Following administration of fluphenazine decanoate, the amount of prodrug at the sites of injection declined exponentially (half-life 3.4 days). Highest concentrations of drug and prodrug were found in iliac and hypogastric lymph nodes nearest to injection sites in which both analytes were detectable 28 days post dose. The half-life for the decline of fluphenazine from lymph nodes (4.6 days) was similar to that from plasma (4.3 days). Following administration of fluphenazine base, only 2.8% of the dose remained at the sites of injection after 2 days. Concentrations of drug in iliac and hypogastric lymph nodes were comparable to those in distal lymph nodes. Fluphenazine concentrations in the lymphatic tissues decreased at about the same rate as plasma concentrations.
CONCLUSIONS: The rate limiting step appeared to be slow partitioning of the decanoate from oily deposits at the injection site and proximal lymph nodes with subsequent hydrolysis of the ester group.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9755905     DOI: 10.1023/a:1011978327504

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  9 in total

1.  Studies on the mechanism of absorption of depot neuroleptics: fluphenazine decanoate in sesame oil.

Authors:  J P Luo; J W Hubbard; K K Midha
Journal:  Pharm Res       Date:  1997-08       Impact factor: 4.200

2.  Pharmacokinetics of haloperidol decanoate in rats.

Authors:  Y Oh-e; H Miyazaki; Y Matsunaga; M Hashimoto
Journal:  J Pharmacobiodyn       Date:  1991-11

3.  Metabolism, distribution and excretion of flupenthixol decanoate in dogs and rats.

Authors:  A Jorgensen; K F Overo; V Hansen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1971

4.  Studies on the fate of vegetable oit after intramuscular injection into experimental animals.

Authors:  O Svendsen; T Aaes-Jørgensen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1979-11

5.  Sensitive method for the simultaneous measurement of fluphenazine decanoate and fluphenazine in plasma by high-performance liquid chromatography with coulometric detection.

Authors:  J P Luo; J W Hubbard; K K Midha
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1997-01-24

Review 6.  Clinical pharmacokinetics of the depot antipsychotics.

Authors:  M W Jann; L Ereshefsky; S R Saklad
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

7.  Fluphenazine enanthate and fluphenazine decanoate: intramuscular injection and esterification as requirements for slow - release characteristics in dogs.

Authors:  J Dreyfuss; J M Shaw; J J Ross
Journal:  J Pharm Sci       Date:  1976-09       Impact factor: 3.534

8.  Absorption of intramuscularly administered [14C]haloperidol decanoate in rats.

Authors:  Y Matsunaga; K Nambu; Y Oh-e; H Miyazaki; M Hashimoto
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Jul-Sep       Impact factor: 2.441

Review 9.  Depot antipsychotic drugs. Place in therapy.

Authors:  J M Davis; L Matalon; M D Watanabe; L Blake; L ] Metalon L [corrected to Matalon
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546

  9 in total
  1 in total

Review 1.  Critical factors influencing the in vivo performance of long-acting lipophilic solutions--impact on in vitro release method design.

Authors:  Susan Weng Larsen; Claus Larsen
Journal:  AAPS J       Date:  2009-11-06       Impact factor: 4.009

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.